Johnson & Johnson has raised its 2026 revenue outlook, citing stronger‑than‑expected sales from its drug and medical‑device portfolio.

The company now projects full‑year sales of $100.8 billion to $101.4 billion, up from the previous range of $100.3 billion to $101.3 billion.

Adjusted earnings per share are now expected to fall between $11.60 and $11.75, a modest lift from the April guidance of $11.45 to $11.65.

The upward revision follows a 6.6% jump in second‑quarter sales, driven by robust demand for its oncology drugs and solid growth in its medical‑device segment.

With the new forecast, investors see a healthier outlook for the company’s diversified product pipeline, and analysts suggest the bump could improve its competitive positioning in both pharma and devices.

Shares of J&J rose modestly after the announcement, reflecting confidence from shareholders that the company’s strong cash flow will support future investment and dividend growth.

The guidance update also underscores the resilience of the broader healthcare market, as companies with diversified portfolios navigate post‑pandemic demand shifts.